Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focusing on neurodegenerative diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company, which specializes in improving mitochondrial health and protecting neuronal function, will present virtually on September 9, 2024, at 7:00 am EST.

Clene's management will deliver a presentation and host one-on-one investor meetings during the conference. Investors interested in scheduling meetings are advised to contact their H.C. Wainwright representative. A webcast of the presentation will be accessible through the 'Events' section of Clene's website, with an additional online registration option available for viewing.

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26^th Annual Global Investment Conference and host 1x1 investor meetings.

Date: September 9, 2024
Time of Presentation: 7:00 am EST
Format: Virtual Presentation
1x1 Meetings: Please contact your H.C. Wainwright representative

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Contacts:

Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310

Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856

FAQ

When is Clene Inc. (CLNN) presenting at the H.C. Wainwright Global Investment Conference?

Clene Inc. (CLNN) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 am EST.

What is the format of Clene's (CLNN) presentation at the H.C. Wainwright conference?

Clene's (CLNN) presentation at the H.C. Wainwright conference will be in a virtual format.

How can investors access Clene's (CLNN) presentation at the H.C. Wainwright conference?

Investors can access Clene's (CLNN) presentation through a webcast available on the 'Events' section of Clene's website or by registering online through the provided link.

What are the main focus areas of Clene Inc. (CLNN)?

Clene Inc. (CLNN) focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

Will Clene (CLNN) be hosting one-on-one meetings at the H.C. Wainwright conference?

Yes, Clene (CLNN) will be hosting one-on-one investor meetings at the H.C. Wainwright conference. Interested parties should contact their H.C. Wainwright representative to schedule.